The market studied is expected to witness CAGR of 6% over the forecast period. The market growth is attributed to the increasing prevalence of motion sickness and growing awareness among the population. Psychological stress is one of the major contributing factors of motion sickness. These psychological factors affect intestinal sensitivity and alteration in the central nervous system. Also, the introduction of novel drug delivery systems such as transdermal patches and adaptation of these dosage forms are expected to bolster the market growth over the forecast period.
Furthermore, the growing number of travellers across the globe, increasing number of surgeries due to chronic conditions is expected to boost the market growth. However, misuse of scopolamine, side effects and stringent regulatory policies are expected to hamper the market growth over the forecast period.
Key Market Trends
Transdermal Patches Anticipated to Grow at Significant Rate
Transdermal patches are widely used nowadays in the treatment of motion sickness. The transdermal patches are prefered due to ease of use, cost-effectiveness and availability. The patch is applied to the hairless skin behind the ear and is used to treat the motion sickness caused by the anaesthesia during the surgeries. According to the world health organization, about 234.2 million major surgeries are performed around the globe every year. Owing to the growing number of surgical interventions across the globe coupled with the launch of new products, the market for transdermal scopolamine patches are expected to grow at a significant rate.
Also, the growing number of domestic and international travellers around the globe and the usage of scopolamine to treat motion sickness during travelling expected to boost market growth over the forecast period.
North America is Expected to have Significant Market Share
North America region is anticipated to have significant market share owing to well-established healthcare infrastructure and the presence of key market players. Also, a growing number of surgeries in the region, an increasing number of travellers coupled with product launches are anticipated to boost the market growth over the forecast period. According to the U.S. Travel Association, U.S. domestic travel has increased by 1.9% in 2018, a total of 2.3 billion person-trips. The Asia Pacific region is expected to grow at significant rates owing to increased expenditure on healthcare, presence of medium and small-sized market players and growing medical tourism for the surgeries in the region.
Global scopolamine market is moderately fragmented and competitive. Market players are focusing on new product launches, product innovations and geographical expansion. The companies operating in the market include Pfizer Inc., Baxter International Inc., Myungmoon Pharm Co Ltd., and Alchem International Pvt. Ltd. among others.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Study Assumptions
1.3 Scope of the Study
4.2 Market Drivers
4.2.1 Growing Number of Surgical Interventions due to Chronic Diseases
4.2.2 Rising Healthcare Expenditure and Adaptation of Scopolamine
4.3 Market Restraints
4.3.1 Side Effects and Misuse of Scopolamine
4.3.2 Stringent Regulatory Policies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.3 Transdermal Patches
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle-East and Africa
5.3.5 South America
220.127.116.11 Rest of South America
6.1.1 Pfizer Inc.
6.1.2 Baxter International Inc.
6.1.3 Myungmoon Pharm Co Ltd
6.1.4 Alchem International Pvt. Ltd.
6.1.5 Caleb Pharmaceuticals, Inc.
6.1.6 GlaxoSmithKline plc.
6.1.7 Phytex Australia
6.1.8 Fine Chemicals Corporation
6.1.9 Perrigo Company plc
6.1.10 Novartis International AG
A selection of companies mentioned in this report includes:
- Pfizer Inc.
- Baxter International Inc.
- Myungmoon Pharm Co Ltd
- Alchem International Pvt. Ltd.
- Caleb Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- Phytex Australia
- Fine Chemicals Corporation
- Perrigo Company plc
- Novartis International AG